comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-31 21:00:23 - browse：3

A hand in pink glove holds a blue rack that contains three tubes of blood samples — first opinion coverage from STAT — Joe Raedle/Getty Images

During my 25 years working in clinical trial operations, I’ve seen the biopharmaceutical world talk a big game about making the process easier for the sites running the trials and the patients participating in them. Everyone from trial sponsors to the Food and Drug Administration has been quick to promise simpler processes, less hassle, and better experiences for everyone involved.

But look closer, and you’ll see that these grand promises often fall apart when sponsors implement complicated plans for collecting blood, tissue and other biospecimens and impossible processes for managing those samples. Behind all the talk and regulatory guidance, there’s a reluctance to change how these essential elements of clinical trial execution are handled, putting the very ideals that sponsors are trying to uphold at risk.

The concept of site and patient centricity frequently gets reduced to addressing only superficial gestures, such as committing to promptly paying sites for their work or using tablets for conducting patient surveys. But the essence of centricity extends far beyond these surface-level measures. It lies in addressing the unseen and unmentioned complexities of clinical trials and providing real solutions that focus on truly prioritizing the needs of trial sites and participants.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： How to fix the rural physician shortage in the U.S.

WSS

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

Xenotransplantation trials will require adjusting expectations, experts say

A public health expert passes on football's full body collisions for youths

Patients, doctors are clashing about side effects of hormonal birth control

A public health expert passes on football's full body collisions for youths

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Wikipedia

Apple is now the first public company to be valued at $3 trillion

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Apple is now the first public company to be valued at $3 trillion

‘Insidious 5’ topples 'Indiana Jones' before ‘Mission: Impossible’ launches

At least 13 dead in Texas as scorching temps continue

Novo: Oral version of Ozempic leads to 15% weight loss

Alkermes shareholders re

Parents surprise family after baby discharged from NICU after 170 days

Trump demands the U.S. pay no more for drugs than other countries … again

Home health providers sue Medicare over payment cuts

hotspot

A public health expert passes on football's full body collisions for youths

See Ryan Reynolds, Hugh Jackman suited up in 1st look at 'Deadpool 3': Photo

Judge agrees to delay next hearing in Trump classified documents case

How to fix the rural physician shortage in the U.S.

Biogen nominates mother of director’s child to replace him on board

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

focus

leisure time

hotspot

focus